Some Of The Most Unnoticed Approach For The GSK1278863

5 (SD 17.0; P to SLx 2119 improvement in DAS28 (reduction ��1.2 units from baseline) was achieved in 92% of patients at week 24, with a mean time to response of 36.4 �� 2.4 days (Figure 2(b)). High disease activity observed in 63 (66.3%) patients at baseline decreased over time, and no patients demonstrated high disease activity at the end of the study. In total, 22 (23.2%) patients had low disease activity (DAS28 ��2.6 to ��3.2) at week 24. The highest proportion of patients reporting low disease activity occurred at week 12 (36%). The GSK1278863 nmr proportion of patients with disease remission (DAS28 Laccase 20 (73%) (Figure 2(b)). Overall, 61 (64.2%) patients achieved disease remission at 24 weeks. Mean time to DAS28 low disease activity and remission was 75 and 90 days, respectively. Figure 2 DAS28 to week 24. (a) Mean score over time. (b) Proportions of patients achieving DAS28 low disease activity (LDA; ��3.2), DAS28 remission ( and clinically meaningful changes from baseline over time (change ��1.2 from baseline). ... The numbers of patients with abnormal values for ESR and CRP at baseline were 80 (84%) and 57 (60%), respectively. By week 4, only 9 (10%) patients had abnormal ESR values and only 10 (11%) patients had abnormal CRP values; these were sustained through week 24 (12% and 11% of patients had abnormal ESR and CRP values, resp., at study end). Mean ESR and CRP levels decreased significantly after the baseline visit, with the lowest levels observed at week 16 for both (P